COMPANY

Zenith Epigenetics

Keywords: oncology prostate cancer carcinoma Metastatic Castration-Resistant Prostate Cancer mCRPC Triple Negative Breast Cancer Lymphoproliferative Malignancies Acute Myeloid Leukemia ZEN003694 ZEN003365

Profile checked Oct 10, 2026

6Trials (company is sponsor)

Timeline

Sep 8, 2021 Trial start Phase 2: ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer source ↗
Nov 12, 2019 Trial start Phase 1/Phase 2: Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol source ↗
Jun 26, 2019 Trial start Phase 2: A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer source ↗
2016-12 Trial start Phase 1/Phase 2: A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer source ↗
2016-05 Trial start Phase 1: A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer source ↗
2014-10 Trial start 1: Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 2 · ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer · NCT04986423
Dec 31, 2027 (ESTIMATED) · Phase 1/Phase 2 · Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol · NCT04145375

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT04145375	Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol	Phase 1/Phase 2	Enrolling by invitation	Nov 12, 2019	Dec 31, 2027 (estimated)
NCT04986423	ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer	Phase 2	Recruiting	Sep 8, 2021	2026-12 (estimated)
NCT03901469	A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer	Phase 2	Terminated	Jun 26, 2019	Mar 7, 2024 (actual)
NCT02711956	A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer	Phase 1/Phase 2	Completed	2016-12	2019-11 (actual)
NCT02705469	A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer	Phase 1	Completed	2016-05	2017-10 (actual)
NCT02238522	Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML	1	Withdrawn	2014-10	2016-06 (estimated)